Drug Trial Radar · NCT07154485
Investigator Initiated Study for the Safety and Efficacy in Frontotemporal Dementia
Last checked: Nov 19, 2026Latest source record: Sep 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
15
Planned (sponsor's estimate)
Start
Oct 1, 2025
Primary completion
Aug 1, 2027
Study completion Aug 1, 2028
Sponsor
- Lead sponsor
- Hee-Jin KimAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Asan Medical Center; Gangnam Severance Hospital; Konkuk University Medical Center
- First posted
- Sep 4, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 55 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics (PK/PD), immunogenicity, and efficacy of multiple intravenous administrations of the investigational drug NS101, compared to placebo, in patients with semantic variant primary progressive aphasia (svPPA), a subtype of frontotemporal dementia (FTD)
Conditions
- Dementia Frontotemporal
Interventions
NS101 IV infusionDrug
NS101 is anti FAM19A5 antibody expected to play as a synapse organizer and reversing synapse dysfunction in various neurological diseases
Placebo IV InfusionDrug
Placebo (i.e. fake drug without active pharmaceutical ingredient) of NS101
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-Emergent Adverse Events (Safety and Tolerability)Time frame: Every Visit for 12month(48weeks)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.